Skip to content
Adrienne Monson – Lifestyle
Author:
Tiziana Life Sciences Ltd.
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
June 25, 2026
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
June 15, 2026
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
May 28, 2026
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
May 21, 2026
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
May 19, 2026
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
May 14, 2026
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
April 16, 2026
←
Previous Page
1
2